Trials involving monoclonal antibodies directed against PD-1 or PD-L1 have shown limited activity in patients with ES, which may be attributable to an overall low tumor mutational burden or PD-L1 expression in ES cells [17,18,20,68]. The gene discussed is CD274; the disease is epithelioid sarcoma.